Home > Oncology > Pfizer’s breast cancer drug Ibrance fails late-stage study

Pfizer’s breast cancer drug Ibrance fails late-stage study

Reuters - 09/10/2020 - Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in early breast cancer patients with residual invasive disease following neoadjuvant chemotherapy, the latest setback in the company's attempt to expand the use of the drug to treat early stages of the disease. Ibrance failed to meet the main goal of improved invasive disease free survival. The PENELOPE-B study compared one year of Ibrance plus at least five years of standard adjuvant endocrine therapy to placebo plus at least five years of standard adjuvant endocrine therapy in 1,250 women with HR+, HER2- eBC at high risk of recurrence who have residual invasive disease after completing neoadjuvant chemotherapy. The latest development comes after an independent data monitoring committee said in May a similar trial comparing Ibrance plus an endocrine therapy to a standalone endocrine therapy to treat early-stage breast cancer was unlikely ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on